Complete index · 50 reports

All RegulationWatch Reports

The complete reporting archive, arranged in a mixed editorial order to surface different companies, enforcement areas and case types.

  1. Drug Promotion

    Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.

    Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.

  2. Drug Pricing

    Public order discloses reversal of $48 million award against OptumRx

    A Florida federal court publicly released an order vacating a $48,362,033 arbitration award against OptumRx entities. The underlying decision was dated September 17.

  3. PBM Rebates

    Express Scripts settled the insulin case without paying a cent or admitting a thing.

    The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.

  4. Antitrust

    States seek approval of Sandoz settlement worth approximately $469 million

    State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.

  5. False Claims Act

    A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.

    Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.

  6. State Enforcement

    Florida sues Pfizer and Albert Bourla over vaccine marketing

    Florida filed a consumer-protection lawsuit against Pfizer and its chief executive. Pfizer disputed the allegations.

  7. Opioid Litigation

    McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.

    The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.

  8. Drug Pricing

    CMS finalises international benchmark model for Medicare Part B drugs

    CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.

  9. PBM Rebates

    Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

    Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

  10. Antitrust

    Caremark wins partial dismissal while Rxeed interference claim survives

    A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.

  11. False Claims Act

    Dompé funded the charities that paid its own drug's copays. It cost $32 million.

    The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.

  12. Drug Pricing

    Fruth reimbursement claims move to arbitration and Missouri federal court

    A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.

  13. Anti-Kickback Statute

    Gilead paid its highest prescribers to speak. The settlement was $202 million.

    The company admitted paying doctors hundreds of thousands of dollars each. It still describes the programs as education.

  14. Drug Pricing

    Arkansas pharmacies sue Express Scripts over alleged reimbursement floor violations

    Twelve Arkansas pharmacies filed a private lawsuit against Express Scripts in Missouri state court, alleging reimbursements below Arkansas's statutory minimum. They seek damages and court-ordered changes; the filing establishes no liability.

  15. Medicare Advantage

    Cigna was accused of billing Medicare for diagnoses it could not support. It paid $172.3 million.

    The settlement includes no admission. Cigna's review found unsupported codes and it left them in place, the government said.

  16. PBM Rebates

    Sixth Circuit keeps Kentucky opioid case against PBMs in federal court

    The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.

  17. Anti-Kickback Statute

    Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.

    The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.

  18. False Claims Act

    Remedi SeniorCare settles federal allegations over prescriptions billed without valid orders

    The Justice Department announced that Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to the United States over allegedly invalid prescription claims. The settlement is based on ability to pay and provides for installment payments without an admission of liability.

  19. PBM Rebates

    Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.

    The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.

  20. False Claims Act

    Abbott agrees to nearly $385 million infant formula settlement

    The Justice Department announced a settlement with Abbott Laboratories over allegedly noncompliant infant formula and nutritional products purchased through government programs. Abbott denied the allegations and did not admit facts or liability.

  21. Opioid Litigation

    AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.

    Allergan had sold its generic opioid business years earlier. The liability stayed, and the settlement carries no admission.

  22. False Claims Act

    Dompé US to pay $32 million over self-disclosed Oxervate co-pay kickbacks

    Dompé U.S. Inc. has agreed to pay $32 million to resolve Department of Justice allegations that it used two patient assistance foundations to cover Medicare co-pays for its drug Oxervate between 2018 and 2021. The conduct was self-disclosed by its Italian parent, and the company admitted certain facts as part of the settlement.

  23. False Claims Act

    Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.

    The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.

  24. PBM Rebates

    Louisiana files federal antitrust suit against Express Scripts and Ascent Health Services

    Louisiana Attorney General Liz Murrill has sued Express Scripts, Inc. and its group purchasing affiliate Ascent Health Services LLC in federal court, alleging a conspiracy with Prime Therapeutics to fix pharmacy reimbursement rates. The complaint also alleges that manufacturer rebates were reclassified as fees and that patients were steered to Express Scripts-affiliated pharmacies.

  25. Patent Litigation

    Pfizer settled with three generic challengers and pushed Vyndamax competition to 2031. No court ruled its patents valid.

    The settlements are private, their terms are undisclosed, and patients keep paying the branded price for up to two more years.

  26. Opioid Distribution

    Walmart agrees $50 million settlement ending DOJ opioid dispensing lawsuit

    The Department of Justice and the Drug Enforcement Administration announced a $50 million settlement with Walmart Inc. resolving allegations that its pharmacies filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act. Walmart also entered a memorandum of agreement with the DEA imposing new compliance obligations and did not admit liability.

  27. False Claims Act

    CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.

    The admission is rare. The penalty, spread over ten years of conduct across the country's largest pharmacy chain, is small.

  28. Antitrust

    Florida sues Prime Therapeutics and Express Scripts over alleged pharmacy price-fixing

    Florida Attorney General James Uthmeier has sued Prime Therapeutics LLC and Express Scripts, Inc., alleging the two pharmacy benefit managers entered a horizontal price-fixing agreement that cut reimbursements to Florida pharmacies. The state seeks injunctive relief, civil penalties, disgorgement and damages.

  29. Antitrust

    Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.

    The deal carries no admission. The company had already reserved for it.

  30. Marketing Fraud

    Veloxis pays over $46 million and enters deferred prosecution over kickbacks

    Veloxis Pharmaceuticals Inc. has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to boost prescriptions of its kidney transplant drug Envarsus XR. The resolution includes a deferred prosecution agreement, a $34.45 million False Claims Act settlement and a $1.55 million Sunshine Act penalty — the largest since the law's passage.

  31. Off-Label Promotion

    Merck's Vioxx penalty was $950 million. It arrived eight years after the drug was pulled.

    Merck pleaded guilty to a misdemeanor. It did not admit the civil allegations about cardiovascular safety.

  32. Antitrust

    Sandoz agrees $450 million settlement with 43 states over generic drug pricing

    Sandoz has agreed to pay about $450 million to resolve antitrust claims brought by 43 US states and territories over alleged price-fixing and market allocation in the generic drug market. The company said the deal contains no admission of wrongdoing and resolves all remaining US government claims against it from the long-running investigation.

  33. Opioid Litigation

    Kentucky's opioid case against two PBMs is going to federal court. Its allegations are still unanswered.

    A Sixth Circuit ruling settles where the case is heard. Two years after Kentucky sued, no court has tested what Express Scripts and Optum actually did.

  34. FTC Enforcement

    FTC pauses OptumRx insulin case to weigh proposed consent agreement

    The Federal Trade Commission withdrew its insulin pricing case against UnitedHealth's OptumRx and its affiliate Emisar from adjudication to consider a proposed consent agreement. The agreement has been approved by the directors of the FTC's competition and consumer protection bureaus but still requires Commission approval, and its terms have not been disclosed.

  35. Anti-Kickback Statute

    Veloxis paid doctors and pharmacies to move a transplant drug, then hid the payments. The bill is over $46 million.

    The resolution includes the largest penalty ever for keeping payments out of the public Open Payments database. It was $1.55 million.

  36. Medicare Negotiation

    Supreme Court declines drugmaker appeals against Medicare drug price negotiation program

    The US Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program created by the 2022 Inflation Reduction Act. The justices left in place Third Circuit rulings dismissing the manufacturers' claims without comment.

  37. Controlled Substances Act

    The Justice Department says CVS filled unlawful opioid prescriptions for over a decade. Nearly two years on, nothing is decided.

    The complaint is an allegation, and CVS denies it. It describes a company whose own pharmacists and data raised the alarm.

  38. Marketing Fraud

    Takeda pays $13.6 million over Trintellix speaker program kickback allegations

    Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve Department of Justice allegations that it paid kickbacks to healthcare providers, in the form of speaker honoraria and high-end meals, to induce prescriptions of the antidepressant Trintellix. The government alleged the conduct caused false claims to Medicare and other federal programmes.

  39. Controlled Substances Act

    McKesson reported 16 suspicious orders out of 1.6 million. The penalty was $150 million.

    It was the company's second settlement for the same failure. The first, in 2008, had required it to build a monitoring system.

  40. State Enforcement

    Texas sues Sanofi over free nurse and support services kickback allegations

    Texas Attorney General Ken Paxton has sued Sanofi-Aventis U.S. LLC, alleging that its Free Nurse Program and Support Services Program amounted to in-kind kickbacks to providers under the Texas Health Care Program Fraud Prevention Act. The state seeks more than $1 million in monetary relief, including civil penalties, and an injunction.

  41. PBM Rebates

    Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

    Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

  42. False Claims Act

    Pfizer pays $59.7 million over Biohaven kickbacks tied to migraine drug Nurtec

    Pfizer agreed to pay $59,746,277 to resolve DOJ allegations that its subsidiary Biohaven, before the acquisition, paid kickbacks to health care providers to induce prescriptions of Nurtec ODT. The government alleged speaker honoraria and high-end meals violated the Anti-Kickback Statute between March 2020 and September 2022.

  43. Drug Pricing

    Oregon seeks $900 million from insulin makers and PBMs over pricing

    Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.

  44. State Enforcement

    Johnson & Johnson pays $700 million to states over talc powder marketing

    Johnson & Johnson agreed to a $700 million settlement with 42 states and the District of Columbia resolving allegations that it deceptively marketed talc-based baby and body powders. The consent judgments permanently bar J&J from making or selling talc-based powders in the United States.

  45. PBM Rebates

    CVS Caremark becomes second major PBM to settle FTC insulin rebating case

    The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.

  46. Drug Pricing

    Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents

    Minnesota Attorney General Keith Ellison announced a settlement with Eli Lilly under which Lilly agreed to cap insulin prices at $35 per month for uninsured Minnesotans and donate insulin to free clinics serving low-income patients. No liability was admitted. The settlement built on Minnesota's 2020 Alec Smith Insulin Affordability Act.

  47. FTC Enforcement

    FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order

    The Federal Trade Commission settled its insulin rebating case against Express Scripts, the Cigna-owned pharmacy benefit manager. The consent order requires formulary, compensation and transparency changes that the FTC estimates will save patients up to $7 billion in out-of-pocket costs over ten years.

  48. Merger Conditions

    Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition

    The FTC finalised a consent order resolving its challenge, joined by six states, to Amgen's $27.8 billion acquisition of Horizon Therapeutics. The order bars Amgen from bundling its products with Horizon's Tepezza and Krystexxa, requires prior approval for related acquisitions and imposes 15-year compliance obligations under a monitor.

  49. FTC Report

    FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny

    The FTC's first interim staff report on pharmacy benefit managers found that the three largest PBMs processed nearly 80% of the 6.6 billion prescriptions dispensed in the US in 2023. The report documented vertical integration with insurers and specialty pharmacies and found PBM-affiliated pharmacies charging substantially higher prices than independents for the same drugs.

  50. Drug Pricing

    Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation

    Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.